Earnings Call Summary | DiaMedica Therapeutics(DMAC.US) Q1 2024 Earnings Conference
Earnings Call Summary | DiaMedica Therapeutics(DMAC.US) Q1 2024 Earnings Conference
There was an increase in research and development expenses to $3.7 million, along with general and administrative expenses of $2.1 million.The following is a summary of the DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript:
以下是DiaMedica Therapeutics Inc.（DMAC）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
DiaMedica reported total combined cash and investments of $46.5 million as of Q1 2024, and working capital of $44.9 million.
Net cash used in operating activities for the quarter was $6.7 million.
There was an increase in research and development expenses to $3.7 million, along with general and administrative expenses of $2.1 million.
DiaMedica報告稱，截至2024年第一季度，現金和投資總額爲4,650萬美元，營運資金爲4,490萬美元。
本季度用於經營活動的淨現金爲670萬美元。
研發費用增加到370萬美元，一般和管理費用增加210萬美元。
Business Progress:
業務進展：
DiaMedica is increasing its clinical trial operations with the addition of 3 experienced personnel and continues its patient enrollment at a healthy pace.
Successful treatment of over 1 million patients with Kailikang in China in 2023 reaffirms its potential.
The company expects a significant number of site activations for its trials in Q3 2024, with the interim analysis set for Q1 2025.
DiaMedica is in the process of legally appealing a recent judgement against them concerning PRA.
DiaMedica通過增加3名經驗豐富的人員來增加其臨床試驗業務，並繼續以健康的速度招募患者。
2023年，凱利康在中國成功治療了超過100萬名患者，這再次證實了其潛力。
該公司預計，其試驗將在2024年第三季度激活大量場地，中期分析定於2025年第一季度進行。
DiaMedica正在對最近對他們作出的有關PRA的判決提起法律上訴。
More details: DiaMedica Therapeutics IR
更多詳情： DiaMedica Therapeutics
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。